Novotech Joins Australian Delegation in Boston

Swiss Biotech Day opened with a big showing by Australian companies. Western Australian Company Linear Clinical Research proudly showcasing WA clinical trials capability.   Australian Trade and Investment Commission (Austrade) Invest and Trade Western Australia Swiss Biotech Association

Clinical research in France: a trusted environment for the trials of tomorrow For international entrepreneurs, biotech founders and investors, clinical development needs speed, predictability—and evidence you can trust. France combines: • EU-aligned regulatory standards and strong trial oversight • High-quality health data and an ecosystem built for evidence generation • Expert clinical centers and experienced investigators across therapeutic areas 🔎 A clear competitive advantage: ⏱️ Certain clinical trials can be authorised in as little as 14 days in France. 👉 Explore why France is a strategic destination for clinical research and life sciences investment. https://ow.ly/XRQW50YH0GZ #ClinicalResearch #ClinicalTrials #LifeSciences #Biotech #Medtech #Investment #ScaleUp #France #HealthInnovation

📢💡[NEWS FROM ACT EU: ACT EU Workplan for 2026-2027 – Version 4, May 2026] The ACT EU workplan for 2026 – 2027 has been adopted by the ACT EU Steering Group and is now published: https://lnkd.in/eXK7gXhq   The workplan reflects the revised ACT EU objectives and takes into account recent legislative and policy developments including the proposed Biotech Act, the Clinical Research Investment Plan (part of the Strategy for European Life Sciences), and the EU4Health initiatives. For more details, please take a look at the updated workplan: https://lnkd.in/eXK7gXhq #clinicaltrials #Europe #drugdevelopment #clinicalresearch #ACTEU

🚨 In recent years, 66 out of 67 European biotech companies chose to go public on markets outside the EU. That single number says a lot about Europe’s life sciences paradox: world-class research, yet most European biotech companies still look beyond Europe when it’s time to grow. BioVox’s latest article dives deeper into this challenge, highlighting why access to funding, stronger growth pathways and better conditions for scaling remain essential if Europe wants to keep innovation here, not just create it. At Biovia, this is exactly where we focus our efforts. Supporting the translation of science into real-world impact — and improving access to funding and scaling opportunities — remains a core priority for us and our ecosystem. The article also points to structural barriers across Europe’s capital markets and regulatory landscape, which continue to shape where and how biotech companies choose to list and scale. ➡️ Get the full breakdown: https://lnkd.in/ed6EUU4n Platforms that bring together research leaders, investors, and policymakers are becoming increasingly important. That's why we look forward to continuing this conversation at Knowledge for Growth, where these challenges—and solutions—will be front and center. “Europe’s life sciences industry is strong, but its future will depend on how well we connect our strengths across borders and sectors.” – Ann Van Gysel 📆 03 & 04 June | 📍 Antwerp 🎫 See you at #KFG2026: https://lnkd.in/gsE4P46

How to make Europe attractive again for biotechs undertaking clinical research? A panel at Arena International Events Group’s #OCTEurope 2026 conference tackled this question. Kamil Sitarz, PhD, MBA, Astrid Pañeda Rodríguez, and Michael Zörer highlighted the wealth of science in Europe, the need to tackle fragmented regulation, and the importance of focusing on Phase I growth. Spain was highlighted as already “making good progress”. The country is considered one of the leading regions in Europe for clinical trials. Stay tuned for more coverage from our reporters in the coming week.

Veritus Research is looking forward to joining Australian Trade and Investment Commission (Austrade) and industry peers in the US next month for the “Exploring New Models of Global Clinical Trial Collaboration” roadshow. Representing Veritus will be Cheryl-Ann Hawkins, our Chief Executive Officer, and Salmaan Naqvi , Chief Commercial Officer, who will be attending sessions across Salt Lake City and Phoenix. The roadshow brings together Australian leaders across clinical trials, CRO services and bioanalysis to engage with US sponsors and partners on practical approaches to global trial delivery and collaboration. Alongside organisations including Accelagen Pty Ltd, Sonic Clinical Trials, Southern Star Research , Prime Financial Group , Pure Solutions Australia , and Crux Biolabs, the sessions will highlight how Australia’s clinical trial ecosystem supports global development programs through: • Efficient study start-up pathways • High-quality, globally recognised data • Strong regulatory clarity • Speed and operational flexibility The program is also supported by BioUtah , Economic Development Corporation of Utah (EDCUtah), Arizona BioIndustry Association (AZBio), and Phoenix Community and Economic Development. 📍 Salt Lake City, Utah - 17 June 2026 Register here: https://lnkd.in/gY8s5tDj 📍 Phoenix, Arizona - 18 June 2026 Register here: https://lnkd.in/g68kJRMQ We continue and look forward to continuing these global collaboration conversations in the US. #ClinicalTrials #AustralianAdvantage #GlobalCollaboration

Europe leads in advanced therapy research, but to stay competitive globally we must strengthen clinical trials, increase visibility of European capabilities, and turn scientific excellence into scalable innovation and investment. Read more about it in the interview with Dr. Montse Daban Marín , President of the Council of European BioRegions - CEBR and the project owner of PRECISEU

MedTech companies : is the US market part of your strategy yet ? 📅 Join us on June 16 for a session organised in collaboration with CALYSTA NV, COVARTIM, IGNITY, Ooho and Wallonia Export & Investment Agency (AWEX).  As MedTech companies start exploring the US market, the complexity becomes real, very fast. What worked in Europe doesn’t always hold in the same way. 🤔 At some point, questions become very practical. Are you building with FDA in mind? Is your go-to-market realistic? Do you actually know where traction will come from? Over the course of an afternoon, we will bring together people who have faced these questions directly, and others who work with companies going through them every day. The discussion will cover : - Strategic positioning and market opportunities - Structuring a credible go-to-market approach - Understanding FDA regulatory pathways and constraints - Anticipating IP and legal risks - Building and leveraging the right network to establish locally - Lessons learned from companies already active in the US 📍 The session will take place on the BioPark campus, within the new impressive EU Biotech Campus infrastructures. Many thanks to them for hosting us. Want to explore the agenda and discover the speakers? 👉 More info & registration:  https://lnkd.in/dKpMzk4e

Looking forward to being back in Salt Lake City, UT and visiting Phoenix, AZ next month with Australian Trade and Investment Commission (Austrade) and peers from the industry for the "Exploring New Models of Global Clinical Trial Collaboration" Roadshow. Utah and Arizona are 2 of the fastest growing states in the US for biotech innovation and Life Sciences - many companies from both states engaging with Australia to take advantage of the many benefits on offer for companies performing Clinical Research. The 'Lunch & Learn' format will engage with local biotech companies and leaders from the Utah and Arizona ecosystems, including representatives from BioUtah, Economic Development Corporation of Utah (EDCUtah), Arizona BioIndustry Association (AZBio) and Phoenix Community and Economic Development - across the course of the events Australian capabilities across Clinical Trials will be presented, with help from leading CROs, Clinical Site, CDMO, Finance and Accounting as well as Bioanalytical and Pathology providers to showcase the turnkey Australian offering. Event Details: - Salt Lake City, UT - 17th June 2026 - 12:00 to 14:00 MT Register Here: https://lnkd.in/gY8s5tDj Phoenix, AZ - 18th June 2026 - 12:00 to 14:00 MT Register Here: https://lnkd.in/g68kJRMQ Southern Star Research will be contributing alongside a panel of industry peers from Sonic Clinical Trials, Prime Financial Group, Veritus Research, Accelagen Pty Ltd, Crux Biolabs #AustralianClinicalTrials #SaltLakeCity #Phoenix #Austrade #Biotech #ClinicalTrials

#CEBioForum 2026 brought together a highly relevant discussion on one of the most important questions for the region: what makes CEE biotech truly investable? Our CEO and Founder, Wojciech Kula, joined the panel “Investing in CEE Biotech: Opportunities & Barriers – De-risking, Not Dreaming” alongside: 👉 Pawel Przewiezlikowski - CEO, Ryvu Therapeutics 👉 Tobiasz Jankowski - Investment Partner, MCI Capital 👉 Piotr Godlewski - Patent Attorney, FGGH IP Patent Attorneys & Attorneys at Law The discussion focused on how investors assess risk in practice, what attracts capital to life sciences companies, and which clinical, regulatory, IP and strategic factors can either build or undermine investor confidence. From Axcellant’s perspective, one point is clear: strong science is only the starting point. To attract investment and scale successfully, biotech and medtech companies need robust clinical strategy, high-quality data, credible development pathways and early identification of execution risks. A sincere thank you to our fellow panellists for their valuable contributions. Their perspectives as a biotech founder, investor and IP expert were crucial in shaping a well-rounded, practical conversation on biotechnology investment. This combination of experience made the discussion especially relevant for companies seeking to move from scientific promise to investable, scalable businesses. A lot is changing in this area in Poland. The biotech industry is attracting increasing investor interest, while more and more medtech and biotech startups are emerging across the region. Thank you also to the organisers of CEBioForum 2026 for creating space for a candid, investor-focused conversation on how we can collectively support the next stage of life sciences growth in Central and Eastern Europe. #CEBioForum #Biotech #MedTech #ClinicalTrials #LifeSciences #CEE #BiotechInvestment #ClinicalDevelopment